HC Wainwright Cuts Keros Therapeutics (NASDAQ:KROS) Price Target to $47.00

Keros Therapeutics (NASDAQ:KROS) had its price objective reduced by HC Wainwright from $100.00 to $47.00 in a research note published on Friday, Marketbeat reports. They currently have a buy rating on the stock.

Other research analysts have also recently issued reports about the company. Bank of America reduced their price objective on Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a research report on Thursday, September 12th. Jefferies Financial Group began coverage on Keros Therapeutics in a research report on Tuesday, November 5th. They set a “buy” rating for the company. Guggenheim reiterated a “buy” rating and issued a $102.00 price objective (up from $96.00) on shares of Keros Therapeutics in a report on Wednesday, December 4th. Cantor Fitzgerald reissued an “overweight” rating on shares of Keros Therapeutics in a research report on Friday, November 22nd. Finally, Scotiabank began coverage on shares of Keros Therapeutics in a research report on Wednesday, October 16th. They issued a “sector outperform” rating and a $77.00 target price for the company. Three investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $85.67.

Keros Therapeutics Stock Performance

Shares of KROS stock opened at $18.83 on Friday. Keros Therapeutics has a 52 week low of $15.67 and a 52 week high of $73.00. The company’s 50 day moving average price is $59.11 and its two-hundred day moving average price is $52.69. The company has a market capitalization of $762.75 million, a P/E ratio of -3.61 and a beta of 1.20.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). The company had revenue of $0.39 million for the quarter. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The firm’s revenue for the quarter was up 4750.0% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.33) EPS. Analysts forecast that Keros Therapeutics will post -5.26 earnings per share for the current year.

Institutional Investors Weigh In On Keros Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of KROS. Charles Schwab Investment Management Inc. grew its holdings in Keros Therapeutics by 14.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 260,120 shares of the company’s stock worth $15,105,000 after purchasing an additional 32,492 shares during the period. Assenagon Asset Management S.A. bought a new position in shares of Keros Therapeutics during the 2nd quarter worth approximately $1,118,000. Intech Investment Management LLC acquired a new position in shares of Keros Therapeutics during the 3rd quarter worth approximately $603,000. Bank of New York Mellon Corp increased its holdings in shares of Keros Therapeutics by 18.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 118,388 shares of the company’s stock worth $5,410,000 after acquiring an additional 18,755 shares during the last quarter. Finally, Point72 Asset Management L.P. raised its stake in Keros Therapeutics by 155.9% in the 3rd quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company’s stock valued at $55,025,000 after acquiring an additional 577,220 shares during the period. 71.56% of the stock is owned by institutional investors.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.